Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06IAQ
|
||||
| Former ID |
DAP000893
|
||||
| Drug Name |
Ambenonium
|
||||
| Synonyms |
Ambenonum; Ambenonium Base; Ambenonium kation; Mytelase (TN); (2-chlorophenyl)methyl-[2-[[2-[2-[(2-chlorophenyl)methyl-diethylazaniumyl]ethylamino]-2-oxoacetyl]amino]ethyl]-diethylazanium; 2,2'-[(1,2-dioxoethane-1,2-diyl)diimino]bis[n-(2-chlorobenzyl)-n,n-diethylethanaminium]
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Myasthenia gravis [ICD9: 358; ICD10:G70.0] | Approved | [538427] | ||
| Therapeutic Class |
Antiarrhythmic Agents
|
||||
| Company |
Sanofi Aventis Us Llc
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C28H42Cl2N4O2+2
|
||||
| Canonical SMILES |
CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl)C<br />C2=CC=CC=C2Cl
|
||||
| InChI |
1S/C28H40Cl2N4O2/c1-5-33(6-2,21-23-13-9-11-15-25(23)29)19-17-31-27(35)28(36)32-18-20-34(7-3,8-4)22-24-14-10-12-16-26(24)30/h9-16H,5-8,17-22H2,1-4H3/p+2
|
||||
| InChIKey |
OMHBPUNFVFNHJK-UHFFFAOYSA-P
|
||||
| CAS Number |
CAS 7648-98-8
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9975, 5106491, 5792527, 8151446, 11113478, 26756578, 29221310, 46508143, 57321160, 76506773, 103107679, 103624065, 104111496, 104222117, 104299694, 117397200, 117465261, 124886912, 126407287, 134338170, 135027862, 136035395, 137005305, 160964456, 162656397, 175265408, 179225494, 196372339, 226628643, 241145075
|
||||
| SuperDrug ATC ID |
N07AA30
|
||||
| SuperDrug CAS ID |
cas=007648988
|
||||
| Target and Pathway | |||||
| Target(s) | Acetylcholinesterase | Target Info | Inhibitor | [536540] | |
| KEGG Pathway | Glycerophospholipid metabolism | ||||
| Cholinergic synapse | |||||
| Pathway Interaction Database | ATF-2 transcription factor network | ||||
| PathWhiz Pathway | Phospholipid Biosynthesis | ||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.